Atherectomy to Angioplasty for Femoropopliteal Disease
Atherectomy to Angioplasty for Femoropopliteal Disease
The primary endpoint of freedom from TLR (including adjunctive stenting) or restenosis at 6 months was met in 77.1% of lesions in the OA group vs 11.5% in the BA group. Compared to BA alone for the treatment of calcium-containing FP lesions, OA pretreatment likely improves lesion compliance and leads to better luminal gain with lower balloon pressures, resulting in a marked reduction of adjunctive stenting. Patency at 12 months with OA therapy is similar to a provisional stent strategy despite minimal stent usage. Avoidance of in-stent restenosis and preserving future treatment options, by not placing a stent, are key advantages of the OA therapeutic approach.
Conclusions
The primary endpoint of freedom from TLR (including adjunctive stenting) or restenosis at 6 months was met in 77.1% of lesions in the OA group vs 11.5% in the BA group. Compared to BA alone for the treatment of calcium-containing FP lesions, OA pretreatment likely improves lesion compliance and leads to better luminal gain with lower balloon pressures, resulting in a marked reduction of adjunctive stenting. Patency at 12 months with OA therapy is similar to a provisional stent strategy despite minimal stent usage. Avoidance of in-stent restenosis and preserving future treatment options, by not placing a stent, are key advantages of the OA therapeutic approach.
Source...